CD8A and melanoma: Given the increase of Ag-specific effector CD8+ T cell responses induced by the triple combination therapy in the non-tumor bearing setting, we next asked whether the combination could induce an antitumor response using the poorly immunogenic B16-OVA melanoma model [21–25].